News
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...
Stocktwits on MSN3d
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZenecaPfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...
The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...
Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in ...
The Nobel Prize winning scientist behind mRNA vaccine technology has attacked the US health secretary’s plan to effectively ...
3don MSN
WASHINGTON -- So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using ...
Health Secretary Robert F. Kennedy Jr.'s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding ...
On Tuesday, the US Department of Health and Human Services disclosed the end of funding for 22 mRNA vaccine projects — a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback